title: [Research progress of anti-angiogenesis drug targets in diabetic retinopathy].
abstract: Diabetic retinopathy is one of the common ocular diseases. One of the pathological characteristic of proliferative diabetic retinopathy is retinal neovascularization which caused visual impairment in diabetic patients. With the anti-VEGF drugs applying in the clinic, it has become one of the main medical treatment of diabetic retinopathy. But it has its limitation. Researchers continue to explore new drug targeting for anti-angiogenesis and try combination therapy or customized treatment. There are many drug targets for anti-angiogenesis, such as promoting angiogenesis factor, integrins and matrix proteinases. Some drugs act on the typical tip cells which is much important in the process of angiogenesis differentiation and proliferation. Overall, these studies opened our view of anti-angiogenesis. The purpose of this article is to summarize the possible drug targets of angiogenesis and the key issues in the study of anti-angiogenic drugs.
authors.affiliation: Department of Ophthalmology, Second Xiang Ya Hospital, Central South University, Changsha 410000, China.
authors.forename: Wenyi
authors.initials: W
authors.lastname: Wu
authors.affiliation: Department of Ophthalmology, Second Xiang Ya Hospital, Central South University, Changsha 410000, China. Email: tangls57@gmail.com.
authors.forename: Luosheng
authors.initials: L
authors.lastname: Tang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D035843:Biomedical Research; D003930:Diabetic Retinopathy / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D015861:Retinal Neovascularization / Q000188:drug therapy* / Q000209:etiology; D042461:Vascular Endothelial Growth Factor A
chemical_list: D020533:Angiogenesis Inhibitors; D042461:Vascular Endothelial Growth Factor A